
Opinion|Videos|September 11, 2024
Real-World Impact of SUNLIGHT Outcomes in mCRC
Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.
Advertisement
Episodes in this series

- The recent SUNLIGHT trial compared FTD/TPI monotherapy to FTD/TPI in combination with bevacizumab for advanced metastatic colorectal cancer. Describe the key takeaways from this trial.
- Include in your discussion overall survival, safety profile, as well as benefit seen regardless of prior bevacizumab therapy.
- How has the SUNLIGHT data impacted your overall use of FTD/TPI in the third-line setting?
- How do the outcomes in SUNLIGHT compare with what you’ve seen as real-word outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Physical Activity, Vaccination May Protect Against Long COVID
2
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
3
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
4
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
5